These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 26475289

  • 41. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E, Ito S, Takai C, Kobayashi D, Nomura Y, Otani H, Abe A, Ishikawa H, Murasawa A, Narita I, Nakazono K.
    Intern Med; 2018 Aug 01; 57(15):2169-2178. PubMed ID: 29607978
    [Abstract] [Full Text] [Related]

  • 42. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W, Sun J, Zhou L, Li Y, Wu X.
    J Clin Pharm Ther; 2016 Oct 01; 41(5):519-23. PubMed ID: 27440710
    [Abstract] [Full Text] [Related]

  • 43. Short-term daily teriparatide in patients with rheumatoid arthritis.
    Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, Tamura Y, Inoue M, Chikuda H.
    Mod Rheumatol; 2018 May 01; 28(3):468-473. PubMed ID: 28805099
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
    Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM.
    Osteoporos Int; 2023 Mar 01; 34(3):573-584. PubMed ID: 36602607
    [Abstract] [Full Text] [Related]

  • 46. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V, Arce-Salinas CA, Espinosa-Ortega F.
    J Clin Densitom; 2014 Mar 01; 17(4):484-9. PubMed ID: 24613450
    [Abstract] [Full Text] [Related]

  • 47. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 01; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 48. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Apr 01; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 49. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
    Mendonça LT, Pinheiro MM, Szejnfeld VL, Castro CH.
    J Clin Densitom; 2017 Apr 01; 20(1):44-49. PubMed ID: 27616291
    [Abstract] [Full Text] [Related]

  • 50. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.
    Intern Med J; 2011 Feb 01; 41(2):186-90. PubMed ID: 20214696
    [Abstract] [Full Text] [Related]

  • 51. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep 01; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
    Ishida T, Yoshida S, Kimura Y, Fujiki Y, Kotani T, Takeuchi T, Makino S, Arawaka S.
    Lupus; 2018 Sep 01; 27(10):1636-1643. PubMed ID: 29954283
    [Abstract] [Full Text] [Related]

  • 57. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb 01; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 58. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 01; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 59. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
    Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.
    J Bone Miner Res; 2013 Jun 01; 28(6):1328-36. PubMed ID: 23281041
    [Abstract] [Full Text] [Related]

  • 60. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.
    Osteoporos Int; 2013 Aug 01; 24(8):2345-52. PubMed ID: 23612793
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.